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Ahallmarkpathologicalfeature ofAlzheimer’sdisease(AD) istheaccumulationofextracellular plaquescomposedoftheamyloid-
beta (Aβ) peptide. Thus, classically experiments were designed to examine Aβ toxicities within the central nervous system (CNS)
from the extracellular space. However, a signiﬁcant amount of evidence now suggests that intraneuronal accumulation of Aβ is
neurotoxic and may play an important role in the disease progression of AD. One of the means by which neurons accumulate
intracellular Aβ is through uptake of extracellular Aβ peptides, and this process may be a potential link between Aβ generation,
synaptic dysfunction, and AD pathology. Recent studies have found that neuronal internalization of Aβ involves lipid rafts and
various lipid raft-associated receptor proteins. Uptake mechanisms independent of lipid rafts have also been implicated. The aim
of this paper is to summarize these ﬁndings and discuss their signiﬁcance in the pathogenesis of AD.
1.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia with a high prevalence rate among the aging
population [1]. The clinical symptoms are characterized by
loss of selective cognitive functions, particularly memory
loss [1]. These traits are accompanied by neuropathological
features observed in postmortem AD brains, including loss
of neurons and synapses in cortical and subcortical regions,
as well as extracellular plaques composed of aggregated
amyloid-beta (Aβ) peptides and intracellular neuroﬁbrillary
tangles that contain hyperphosphorylated Tau protein [2].
Although the precise role of Aβ in AD etiology remains
inconclusive, the current consensus is that it is a central
player in the development of the disease. This hypothesis
is supported by a variety of transgenic mouse lines that
containmutationsintheAβprocessing machinery [3].These
mice display some of the neuropathologies and behavioral
deﬁcits similar to that observed in AD patients, provid-
ing a link between abnormal Aβ production and disease
development [3]. Nevertheless, the cellular events that occur
between production of the Aβ peptide and degeneration
of a neuron remain inconclusive. Aβ is produced from its
membrane-embedded precursor, amyloid precursor protein
(APP), through sequential cleavage by enzyme complexes
β-a n dγ-secretases [4]. Two distinct cleavage pathways
exist. In the nonamyloidogenic pathway, APP is cleaved
by α-secretase resulting in an 83-amino-acid C-terminal
fragment that is further cleaved by the γ-secretase into a
short p3 peptide [5]. In the amyloidogenic pathway, the
cleavage occurs at 99 rather than 83 amino acids from the
C-terminus and is mediated by the β-secretase [6]. This
results in a 99-amino-acid peptide that contains an intact
hydrophobic region termed the Aβ region [6]. Subsequent
cleavage by γ-secretase releases this peptide region forming
the Aβ peptide normally 40-amino-acids in length (Aβ40)
[6]. An alternate cleavage by the γ-secretase results in a
less abundant form of the peptide 42 residues in length
(Aβ42) [7]. Aβ42 is more hydrophobic and has a greater
tendency to aggregate into ﬁbrils and plaques compared
to Aβ40 [7]. Aβ42 is also the prevalent isoform found in
the amyloid plaques of AD patients [8]. Several hypotheses2 International Journal of Alzheimer’s Disease
have been proposed in regards to how Aβ production leads
to neuronal degeneration and toxicity: Aβ monomers are
known to aggregate into higher-molecular weight oligomers
and ﬁbrils [9]. The hydrophobicity of Aβ allows it to target
neurons directly; extracellular Aβ aggregates can interact
with neuronal membranes resulting in disruptions in bilayer
permeability [10]. Aβ oligomers and ﬁbrils also bind to
several membrane proteins which may induce change or loss
of protein function [11].
2.Sourcesof IntracellularAβ
Despite evidence suggesting that Aβ exerts its eﬀects extra-
cellularly, reports have shown that Aβ in the intraneuronal
compartment may play an important role. As early as the
1980s, researchers have observed that in AD patients, Aβ
deposition inside the cells precedes its accumulation in
the extracellular space [12, 13]. The ﬁndings in human
subjects are corroborated by transgenic mouse models of
AD, where intraneuronal Aβ is commonly observed. Various
mousemodelsdisplayAβdepositsinside neuronswell before
the appearance of extracellular plaques [14–21]. In the
triple transgenic (3xTg) AD mice, the level of intraneuronal
Aβ is found to correlate with synaptic dysfunction and
memory impairment [21, 22]. In spite of these observations,
the concept that intraneuronal Aβ contributes to disease
progression has not been ubiquitously accepted. One large-
scale human study found contradicting evidence, such that
the level of intraneuronal Aβ increases with age even in non-
AD individuals [23], suggesting that Aβ inside neurons may
not have a pathological role. This might be explained by the
fact that some ﬁxation and staining methods detect Aβ in
the extracellular space more strongly than inside cells [24–
26].Forexample,studieshaveshown thatexposuretoformic
acid, which is a commonly used step in Aβ staining, does not
yield the strongest intracellular Aβ signal whereas antigen
retrieval by heating enhances the signal [24, 25]. Bayer and
Wirths [26] suggested that in transgenic mice studies, brains
arenormally ﬁxedbycardiac perfusion inashort timeframe,
leading to more frequent observations of intraneuronal Aβ
in mouse models than in human tissues that are exposed to
extended periods of postmortem ﬁxation.
Although the role of intraneuronal Aβ in disease devel-
opment is controversial, there is no dispute regarding the
presenceofAβ within neurons.The keyquestionthatfollows
is the origin of the accumulated Aβ inside neurons. Thus far
it is unclear whether the accumulation originates from direct
deposition of Aβ intracellularly or from uptake from the
extracellular Aβ pool. In addition to the plasma membrane,
APPisalso foundonmembranesofmitochondria, thetrans-
Golgi network, endoplasmic reticulum (ER), endosomes,
autophagosomes, and lysosomes [27]. β-a n dγ-secretases
have been found in these subcellular compartments [27];
hence Aβ production occurs intracellularly as well. Endo-
somes in particular are hypothesized to be a major site of
Aβ production due to their acidic pH and coexpression
of both β-a n dγ-secretases [27]. Studies have shown that
internalization of APP from the plasma membrane to endo-
somes can occur via endocytosis, and that blockade of this
process reduces intracellular Aβ levels [28]. Coexpression of
β-a n dγ-secretases isalso found in theGolgi [27], suggesting
that the secretory pathways are also potential sites of Aβ
production. Intracellular traﬃcking of APP may act as a
cellular mechanism that regulates the production of Aβ since
some cellular compartments have optimal conditions for
APP cleavage while others do not. Nonetheless, there is no
question that a signiﬁcant amount of APP is cleaved at
the plasma membrane resulting in extracellular deposition
of Aβ.O n ep o s s i b l ef a t eo fd e p o s i t e dA β is re-entry into
cells. Glial cells including astrocytes and microglia are the
putative phagocytic cells in the CNS. Extracellular Aβ can
be internalized by glial cells via phagocytosis as well as
pinocytosis and endocytosis [29–31]. A signiﬁcant portion
of deposited Aβ is likely taken up by glia. Neurons, on the
other hand, are not generally considered phagocytic cells.
Nonetheless, reportshaveshown thatAβ uptakecan occurin
neurons contributing to the accumulation of intraneuronal
Aβ [6, 26].Due to theirpotential signiﬁcance in ADetiology,
the cellular mechanisms that mediate neuronal Aβ uptake
have garnered increased attention in recent years. Current
data suggest that the majority of Aβ uptake mechanisms in
neuronsinvolvemembranemicrodomainstermedlipidrafts.
3.LipidM etabolism,LipidRafts,andAD
Lipid rafts are mobile microdomains in plasma or organelle
membranes that are rich in cholesterol and sphingolipids
[32]. This specialized lipid composition distinct from the
surrounding membrane phospholipids allows lipid rafts to
associate with select groups of proteins [32]. Lipid raft-
associated proteins have key roles in protein entry and
traﬃc k i n ga sw e l la ss i g n a lt r a n s d u c t i o n[ 32]. The idea
that lipid rafts may be associated with Aβ metabolism
originated from cholesterol studies [32]. In AD patients,
serum cholesterol levels correlated with Aβ load in the
brain [33]. Individuals with high cholesterol levels during
midlife are at a higher risk to develop AD later in life
[34], whereas individuals treated with cholesterol lowering
drugs have a lower prevalence of AD [35, 36]. Similar
trends were observed in animal and cell culture models [32].
Notably, accumulation of intraneuronal Aβ was increased in
transgenic AD mice fed with a high cholesterol diet [37, 38].
Despite evidence supporting a role for cholesterol in AD
pathogenesis, clinical use of cholesterol-lowering statins to
treat AD patients has not yielded consistent results [39].
Furthermore, postmortem analyses of AD brains showed that
cholesterol levels in the hippocampus and the frontal cortex
were not signiﬁcantly diﬀerent from that of age-matched
controls [40, 41]. Although the precise role of cholesterol in
AD is unclear, the discovery of β-secretase, γ-secretase, and
APP at lipid rafts suggests that cholesterol is involved in APP
processing and Aβ production [42–44]. Indeed, cholesterol
depletion in cultured neurons decreases the production of
Aβ [45]. Cholesterol depletion is a commonly used method
to compromise lipid raft integrity and has been shown to
dissociate γ-secretase from lipid rafts [44, 46]. Increased
targeting of β-secretase to lipid rafts promoted its cleavage
activity of APP [47]. Studies have also found that unlikeInternational Journal of Alzheimer’s Disease 3
APP cleavage, which occurs mostly at lipid rafts, non-APP
substrates of the γ-secretase were cleaved at non-lipid raft
domains [44]. Lipid rafts may thus serve as a platform




In addition to processing of APP, lipid rafts have been
proposed as a site for binding of extracellular Aβ and a niche
for Aβ aggregation [11, 48]. Exogenously applied oligomeric
Aβ has been shown to concentrate at lipid rafts of cultured
neurons [49]. Lipid rafts isolated from AD mice are also
concentrated with soluble nonﬁbrillar Aβ [50]. Sphingolipid
derivatives such as sphingomyelin and gangliosides can
readily bind both soluble and ﬁbrillar Aβ and are thought
to be the major Aβ-recruiting component in lipid rafts
[51–54]. Cholesterol has also been shown to interact with
soluble and ﬁbrillar Aβ [55]. Gangliosides, in particular
monosialotetrahexosylganglioside (GM1), is known to form
an “Aβ-seed” by complexing with soluble Aβ [51, 52].
GM1-bound Aβ (GM1/Aβ)h a sad i ﬀerent conformation
than that of soluble Aβ and seeds the formation of Aβ
aggregates [51, 52]. Binding of Aβ to lipid rafts has been
shown to promote its oligomerization and subsequently
ﬁbril formation, possibly via the seeding and aggregation-
promoting eﬀect of GM1/Aβ [56, 57]. Disruption of lipid
raftsin culturedpheochromocytoma cells wasable toprotect
them against toxicity induced by Aβ oligomers [58, 59].
The interaction of Aβ with lipid rafts may induce toxicity
via several mechanisms: Aβ aggregation at lipid rafts can
induce membrane perturbations by oxidative damage [60,
61]. Alternatively, interaction of Aβ oligomers with GM1
decreases membrane ﬂuidity and in turn stimulates APP
processing, resulting in a vicious cycle of Aβ overproduction
[62]. It has also been suggested that rather than aggregating
on the cell surface, a portion of the Aβ binding to lipid rafts
is internalized [63]. One of the earlier studies examining
Aβ internalization observed that in human ﬁbroblast cells,
Aβ accumulated intracellularly were in a high-molecular
weight oligomeric state [64]. A later study using human
neuroblastoma cells showed that not all of the applied
exogenous Aβ oligomers were internalized; the oligomers
bound to the membrane formed aggregates larger than the
internalized oligomers [63]. These ﬁndings suggest that Aβ
uptake may precede its aggregation at the membrane, and
that surface aggregation of Aβ takes place as a result of
saturation of the uptake pathway. The authors also demon-
strated that oligomeric Aβ was internalized more eﬃciently
than ﬁbrillar Aβ [63]. Saavedra et al. [65] in a study using
cervical sympathetic neurons found that internalized Aβ
oligomers colocalized with cholera toxin subunit B (CTxB),
a lipid raft marker that speciﬁcally binds to GM1, suggesting
that Aβ internalization occurs at lipid rafts, possibly via
GM1 binding. The authors further showed that reduction
of cellular cholesterol and sphingolipid levels signiﬁcantly
decreased Aβ uptake [65]. A recent study by Singh et al. [66]
using mouse neuroblastomas also found colocalization of
internalized Aβ with CTxB. The authors pharmacologically
inhibited lipid raft-dependent endocytosis which resulted in
decreased uptake of soluble Aβ [66]. Thus far it is unclear
whether the lipid components or the associated receptor
proteins are responsible for initiating Aβ uptake at lipid
rafts. Aβ, in addition to lipids, can bind to a wide range
of membrane proteins [11], which may act as carriers of
Aβ upon endocytosis of the Aβ-receptor protein complex.
The following section discusses the various routes of cellular
entry for extracellular Aβ.
5.Mechanisms ofAβ Uptake
5.1. Glutamate Receptors. One of the earliest pathological
features in AD that coincides with accumulation of intra-
neuronal Aβ is synaptic aberrations including changes in the
shape and the protein composition of synapses as well as
an overall decrease in abundance. Application of exogenous
soluble Aβ to hippocampal slices leads to Aβ accumulation
in CA1 neurons coupled with decreased expression of the
synaptic marker synaptophysin [67]. Extracellular Aβ may
thus preferentially target synapses. There is a wide range
of lipid raft-associated receptors localized at the synaptic
membrane. One receptor that is highly expressed at synapses
is the N-methyl-D-aspartic acid (NMDA) receptor for the
neurotransmitter glutamate. NMDA receptors are associated
with lipid rafts [68, 69]. Exposure of the NMDA receptor
to Aβ oligomers is known to promote endocytosis of
the receptor as well as other signaling events associated
with NMDA receptor traﬃcking [28]. In hippocampal
slices treated with soluble Aβ, cotreatment with an NMDA
receptor antagonist prevented the neuronal accumulation
of Aβ, suggesting that activation of the receptor by Aβ
may trigger endocytosis of the Aβ-NMDA receptor com-
plex [70]. However, whether Aβ actually binds to NMDA
receptor is unclear. In a study examining the eﬀects of Aβ
oligomers on primary hippocampal neurons, Lacor et al.
[71] noted that the binding sites of Aβ oligomers overlap
with immunoreactivity of NMDA receptor 1 (NR1), a
subunit of the NMDA receptor, and postsynaptic density-95
(PSD-95), an anchoring protein associated with the NMDA
receptor. This would suggest physical associations between
Aβ and the NMDAreceptor. However, colocalizationand co-
precipitationofthetwoinanintracellularcompartmenthave
not been demonstrated. Some hypothesized that the NMDA
receptor and its associated signaling cascades interact with
Aβ via another Aβ-binding receptor protein. In the study by
Bi et al. [70], cotreatment of antagonists against integrins
with soluble Aβ nearly doubled the amount of internalized
Aβ compared to Aβ treatment alone. As NMDA receptor
antagonist yielded opposite trends, the authors hypothesize
that membrane integrins and the NMDA receptor modulate
Aβ uptake cooperatively [70]. Integrins are associated with
lipid rafts as well [72]. Aβ is known to bind integrins directly
[73], and in addition to regulating Aβ uptake, integrins
also modulate the neurotoxic eﬀects of soluble Aβ [70].
There iscurrentlynodatasuggesting thatintegrins physically
interact with the NMDA receptor despite evidence showing
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and traﬃcking [74–76]. Therefore, it is possible that both
receptors act as Aβ carriers butat thesame time induceother
signaling cascades independent of the uptake process.
Another glutamate receptor modulated by integrin
signaling is the α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate (AMPA) receptor [76–78]. The AMPA and
NMDA receptors are often co-expressed by the same gluta-
matergic synapses. Like NMDA receptors, AMPA receptors
are closely associated with lipid rafts and GM1 in particular
[68, 79–81]. However, AMPA receptor recycling to and from
the synaptic surface is fast compared to that of NMDA
receptors, suggesting that AMPA receptors may act as a
more eﬃcient carrier of Aβ than NMDA receptors [82].
In a study using primary hippocampal neurons, Zhao et
al. [82] showed that AMPA receptor traﬃcking is regulated
by Aβ oligomers. Antagonists against the AMPA receptor
inhibited Aβ internalization as in the case with NMDA
receptor antagonists [82]. The authors further demonstrated
that the glutamate receptor 2/3 (GluR2/3) subunit of AMPA
receptors co-immunoprecipitated with Aβ oligomers [82],
implicating a role for AMPA receptors as an Aβ carrier.
Several other research groups have also reported endocytosis
ofAMPAreceptorsinducedbyAβoligomers[83,84],leading
to the speculation that endogenousAβ at physiological levels
may have essential roles in the maintenance of synapses. A
recent study demonstrated that in mice overexpressing APP,
the density of dendritic spines is increased at a young age
before accumulation of Aβ nulliﬁes the eﬀect at an older age
[85]. Hence it is possible that APP at synaptic membranes
promotes surface expression and stabilization of glutamate
receptors, while cleavage of APP and synaptic release of
Aβ would promote opposite eﬀects. The uptake of Aβ by
glutamate receptors may serve as a regulatory mechanism
that prevents Aβ-induced synaptic depression.
5.2. Acetylcholine Receptors. Another neurotransmitter
receptor implicated in the uptake of Aβ is the α7 nicotinic
cholinergic receptor (α7nChR) for the neurotransmitter
acetylcholine. The role of acetylcholine and its receptors
have received continuous attention in the AD ﬁeld due to
the high susceptibility of cholinergic neurons to degenerate
in AD pathology [86]. Several hypotheses have been formed
to explain this regional transmitter-speciﬁc vulnerability.
It has been proposed that cholinergic signaling modulates
APP processing [86]. Conversely, Aβ can aﬀect acetylcholine
release from the presynaptic terminal as well as signaling
of nicotinic receptors in the postsynaptic compartment
[86]. The α7nChR in particular is known to bind soluble
Aβ with high aﬃnity [87, 88], leading to the speculation
that Aβ may be internalized via complex formation
with the α7nChR. Nagele et al. [89]i n v e s t i g a t e dt h i s
possibility in a study examining both human AD tissues
and human neuroblastoma cells. The authors found that
immunoreactivity of α7nChR and Aβ is highly colocalized
in neurons of the hippocampus, entorhinal cortex, and
cerebellum [89]. They observed similar ﬁndings in vitro;i n
neuroblastoma cells transfected with α7nChR, soluble Aβ
treatment induced large punctate staining of α7nChR which
colocalized with Aβ immunoreactivity [89]. Untransfected
cells exhibited slower internalization of Aβ and lower
susceptibility to Aβ-induced toxicity, suggesting a role
for α7nChR as an Aβ carrier [89]. Although subcellular
colocalization of Aβ and α7nChR has not been reported,
circumstantial evidence indicates that neurotoxic eﬀects of
intracellular Aβ are mediated at least partly by uptake via
α7nChR independent of its agonist eﬀects. For instance,
binding of α7nChR by Aβ results in primarily neurotoxic
eﬀects, yet paradoxically, binding of the same receptor by
other competing agonists promotes neuroprotection [90].
Another study showed similar paradoxical results where
disruption of lipid rafts attenuated Aβ-mediated α7nChR
signaling but not nicotine-mediated signaling [91]. An
explanation for this paradox is that the toxic eﬀects of
Aβ on cholinergic synapses occur after internalization
by cholinergic receptors, and that activation of the
receptor upon Aβ binding at common agonist sites
triggers other independent pathways. This explanation
may also justify contradictory ﬁndings in animal studies,
where transgenic AD mice deﬁcient in α7nChR expression
exhibited exacerbated AD pathology in one report [92]a n d
ameliorated pathology in another [93].
5.3. Apolipoproteins. A group of proteins implicated in
the traﬃcking of Aβ that are not localized to synaptic
membranes are apolipoproteins. As implied by the nomen-
clature, the amphipathic nature of apolipoproteins enables
them to bind and transport lipids within a water-soluble
milieu. Some apolipoproteins act as soluble chaperones for
hydrophobic peptides such as Aβ [94]. In nonfamilial AD,
the ε4 allele of the gene encoding apolipoprotein E (apoE)
is the most prevalent genetic risk factor [94]. Consequently,
the potential link between apoE function and Aβ toxicity
hasbeen studiedextensively.Transgenic ADmicedeﬁcientin
apoE display reduced Aβ load, suggesting a role for apoE in
promoting Aβ accumulation [95]. Isoform-speciﬁc proper-
ties ofthe apoE4 allele were also investigated: binding studies
comparing diﬀerent apoE isoforms showed that apoE2 and
apoE3 bind soluble Aβ more eﬃciently than apoE4 that
preferentially binds to an intermediate aggregate form of Aβ
[96, 97]. An in vitro study on puriﬁed synaptosomes showed
that soluble Aβ,b u tn o tﬁ b r i l l a rA β, complexes with apoE,
and that formation of the apoE-Aβ complex is crucial in
the capacity of apoE3 to promote Aβ internalization [98].
T h ea u t h o r so b s e r v e dt h es a m et r e n di ni n t a c tn e u r o n s
of the dorsal root ganglia [98]. The capacity of apoE to
promote uptake of soluble Aβ is isoform-dependent; in the
case of apoE4, promotion of uptake requires proteolytic
cleavage [99]. In tissues of AD patients, immunoreactivity
of apoE strongly correlates with that of intracellular Aβ,
suggesting that apoE is internalized with Aβ [100]. Whether
Aβ en t er sn eur on sa sac om ple xwi tha poEora sac h a per on e-
free entity is unclear. The receptor that mediates apoE-
dependent internalization of Aβ is also undeﬁned. Similar
to Aβ, apoE does not appear to have a dedicated receptor
but is known to bind several putative receptor proteins.
In transgenic AD mice, apoE is found to accumulate in
lipid rafts suggesting that the apoE-Aβ complex may target
raft-associated receptor proteins [50]. Moreover, apoE hasInternational Journal of Alzheimer’s Disease 5
been observed to target neurotransmitter receptors such as
α7nChR [90], leading to the hypothesis that uptake of Aβ
by neurotransmitter receptors results from apoE-receptor
binding rather than direct interaction between Aβ and
the receptor. The surface receptors most often associated
with apoE are the low-density lipoprotein receptor-related
proteins (LRPs), a family of multiligand receptors known
to have a high endocytosis rate [101]. LRP1 in particular
has several known roles in AD. For instance, LRP1 binds to
APP at the cell surface and subsequent endocytosis targets
APP to the lysosome, modulating Aβ production [101]. The
same endocytic mechanism is thought to mediate the uptake
of Aβ. Gylys et al. [98] showed that addition of receptor-
associated protein (RAP), an antagonist of LRP1, along with
theapoE-Aβcomplexsigniﬁcantlyreducedinternalizationof
soluble Aβ. A recent study in neuroblastoma and neuronal
cell lines observed similar trends, such that RNAinterference
of LRP1 inhibited and overexpression of LRP1 stimulated
soluble Aβ uptake [102]. In vivo experiments found that
AD mice overexpressing LRP had increased intraneuronal
accumulation of Aβ [103]. It has been suggested that LRP1
may bind soluble Aβ directly without chaperones. Binding
assays, however, showed otherwise [104] ,a n di na na p o E -
free environment, LRP inhibition did not alter Aβ uptake
[65], suggesting that formation of the apoE-Aβ complex is
required for internalization by LRP1. Notably, LRP1 asso-
ciates with lipid rafts transiently such that it traﬃcs between
raft and nonraft membrane domains [105]. The motility of
LRP1 may serve as a mechanism to regulate its availability to
Aβ. The LRP antagonist receptor-associated protein (RAP),
in addition to its LRP-modulating activities, has molecular
properties similar to chaperone proteins like apoE. Kanekiyo
andBu[106]showed thatRAPformscomplexeswithsoluble
Aβ much like apoE and similarly promotes Aβ uptake into
neuroblastoma cells. They further demonstrated that uptake
of soluble Aβ with RAP is independent of LRP1 [106],
which is somewhat surprising as RAP is routinely used
experimentally to inhibit LRP1 activity. The precise route of
entry for RAP-Aβ c o m p l e x e si st h u su n c l e a r .
5.4. Other Aβ-Binding Proteins. The proteins implicated in
Aβ uptake represent only a small percentage of soluble
and membrane proteins that physically interact with Aβ.
The list of Aβ-binding proteins is extensive (see [11]f o r
a review). One notable receptor protein implicated in
neuronal internalization of Aβ is the receptor for advanced
glycation end products (RAGE). RAGE is a member of
the immunoglobulin superfamily that interacts with several
classes of ligands [107]. Complex formation between RAGE
and soluble Aβ has been demonstrated [108]. Neuronal
overexpression of RAGE in transgenic AD mice results in
exacerbated AD pathology [109], suggesting that RAGE
maypromoteintracellularAβ accumulation.To demonstrate
the role of RAGE in Aβ uptake, Takuma et al. [107]
derivedprimary corticalneuronsfromRAGE-deﬁcientmice,
showing that neurons without RAGE expression internalized
markedly less soluble Aβ compared to wild-type neurons.
Interestingly, while internalization facilitated by most recep-
tors appeared to localize to lysosomes, the authors showed
by electron microscopy that Aβ internalized by RAGE
accumulates in the mitochondria [107]. Accumulation of
Aβ in the mitochondria is a well-documented occurrence
(reviewedin[110]).Mitochondriaarecloselyassociatedwith
theER[111],henceitis possible thatAβ inthe mitochondria
originates from endosome-Golgi and Golgi-ER vesicular
transport. However, since mitochondria are not classically
associated with the endosomal pathways, it is proposed that
mitochondrial Aβ derives from transport of cytosolic Aβ.
Althoughmitochondriahavebeenshowntoimportcytosolic
Aβ via translocases [112], it is unclear how extracellular Aβ,
which enters the cell by endocytosis of RAGE, translocates
out of the endo-lysosomal compartments into the cytosol.
Localization of internalized Aβ to the mitochondria may not
be speciﬁc to RAGE endocytosis; therefore, future studies
need to determine whether Aβ endocytosed through other
receptor proteins also localize to mitochondria.
The serpin-enzyme complex receptor(SEC-R)isanother
less documented protein implicated in the uptake of Aβ
[113]. It was originally identiﬁed in leukocytes as a receptor
for antiprotease enzymes. Although SEC-R is also expressed
in neurons [113], its role in neuronal cells and Aβ-associated
processes is unknown. Boland et al. [113] showed that SEC-
R binds to soluble Aβ and promotes uptake in pheochromo-
cytoma cells. Whether SEC-R functions similarly in neurons
has not been determined. A recent study reported that mul-
tiple epidermal growth factor-like domains 10 (MEGF10),
a newly identiﬁed receptor involved in clearance of cell
corpses,alsomodulatessolubleAβuptake[66].Althoughthe
authors show expression of MEGF10 in neurons of the hip-
pocampus,itisunclearwhetherMEGF10physicallyinteracts
with Aβ, and henceforth whether MEGF10 mediates Aβ
uptake or merely modulates the process.
5.5. Endocytic Pathways of Aβ. A topic that has generated a
signiﬁcant amount ofinterest concernsthespeciﬁc endocytic
pathways involved in Aβ uptake. Endocytosis is a well-
studied phenomenon in cell biology and to date several
distinct pathways involving diﬀerent protein machinery
have been identiﬁed (for a review see [114]). The classical
endocytic pathway involves invagination of the plasma
membrane at the site of the receptor-cargo binding; the
invaginated vesicle is then coated with adaptor proteins,
which recruit guanosine triphosphatases (GTPases) that
provide the necessary energy to facilitate cleavage of the
vesicle from the cell membrane and delivery to endosomes
or other subcellular compartments [114]. By far the most
frequently reported process is dependent on clathrin and
dynamins [114]. Clathrin is an adaptor protein that forms
theprimary component ofthevesiclecoating complex[114].
Dynamins are responsible for the membrane cleavage to
release the invaginated vesicle from the plasma membrane
[114]. Endocytosis at lipid rafts, however, is thought to pro-
ceed in a clathrin-independent manner (reviewed in [115]).
Invaginations formed from lipid rafts, termed caveolae, are
rich in cholesterol and sphingolipids and are morphologi-
callydistinctfromclathrin-coatedinvaginations [115].Cave-
olins are the major protein component of caveolae and are
thought to cooperatively regulate lipid raft endocytosis with6 International Journal of Alzheimer’s Disease
Table 1: Summary of receptor proteins involved in the neuronal uptake of Aβ.
Receptor proteins involved in neuronal Aβ uptake









NMDA receptor probable nonaggregated,
oligomeric no data hippocampal slices clathrin-dependent
AMPA receptor yes Oligomeric yes hippocampal
neurons clathrin-dependent
integrins yes non-aggregated no data hippocampal slices clathrin-dependent
α7nChR yes non-aggregated no data neuroblastomas both clathrin-dependent
and independent
LRP1 via apoE non-aggregated no data DRG neurons,
neuroblastomas clathrin-dependent
RAGE yes non-aggregated no data cortical neurons no data
MEGF10 no data non-aggregated no data neuroblastomas raft-dependent/
caveolin-independent
Soluble receptors




RAP yes non-aggregated no data neuroblastomas no data
cholesterol and gangliosides [115]. It was originally thought
that endocytosis at lipid rafts are caveolin- and dynamin-
dependent. However, there is increasing evidence suggest-
ing a caveolin-independent dynamin-dependent pathway as
well as a ﬂotillin-dependent dynamin-independent pathway
[114]. The notion that lipid raft endocytosisdoesnot involve
clathrin has also been challenged as studies have observed
clathrin-dependent endocytosis of lipid raft-associated pro-
teins [116, 117].
Among receptor proteins that mediate Aβ uptake, LRP1
has been shown to endocytose Aβ via a clathrin-dependent
process; neuroblastoma and neuronal cell lines deﬁcient in
clathrin internalized signiﬁcantly less soluble Aβ as well as
LRP1[102].Requirementforclathrinhasalso beenshown in
endocytosisoftheNMDAandAMPAreceptorsforglutamate
[118]. Not all routes of Aβ uptake, however, are clathrin-
dependent. In the case of α7nChR, in Chinese hamster ovary
cells transfected with α7nChR, endocytosis of the receptor
occurs in the absence of clathrin, and in fact, dynamins as
well [119]. This contradicts an earlier study in α7nChR-
transfected human neuroblastomas that reported inhibition
of α7nChR endocytosis along with decreased soluble Aβ
internalization by treatment with phenylarsine oxide, an
inhibitor of clathrin-coat formation [89]. It is possible that
both pathways mediate α7nChR endocytosis and that the
speciﬁc cell type can determine which pathway is domi-
nant. Clathrin-independent internalization of Aβ has been
reported in several diﬀerent neuronal cell types. In mouse
neuroblastoma cells, neither knockdown of clathrin nor
inhibition of AP180, a clathrin-associated assembly protein,
had an eﬀect on internalization of oligomeric Aβ [120]. The
authors reported that inhibition of dynamin and RhoA, a
small GTPase, decreased the uptake of Aβ oligomers into the
cell [120]. These data suggest that Aβ can be internalized
through an IL-2 receptor-β-like endocytic pathway depen-
dent on lipid rafts, dynamins, and RhoA [115]. In cervical
sympathetic neurons, Saavedra et al. [65] also reported that
uptake of Aβ oligomers is independent of clathrin. A role
for dynamins is again implicated, as expression of dominant
negative dynamin mutant decreased Aβ internalization [65].
The authors further demonstrate that the internalized Aβ
oligomers colocalized with lipid rafts, but not caveolins
[65]. This dynamin-/raft-dependent caveolin-independent
pathway has also been demonstrated in MEGF10-mediated
uptake of soluble Aβ [66] and is likely similar to the IL-2
receptor-like pathway [120]. Collectively these data show
that in the absence of clathrin-associated receptors, neurons
endocytose Aβ predominantly at lipid rafts via caveolin-
independent mechanisms. Clathrin-dependent endocytosis
of Aβ can occur, but it is uncertain whether it takes place
at lipid rafts. Notably, internalization of Aβ oligomers in
cervical sympathetic neurons preferentially occur in axons
[65] while in primary hippocampal neurons and neuron-
like cell lines described in other reports, the uptake appears
to occur in dendritic synapses and cell bodies. These results
suggest that endocytic mechanisms are varied not only in
diﬀerent types of neurons, but in diﬀerent parts of the
neuron.
Aside from endocytosis, an unconventional route of Aβ
uptakewasproposed by Kandimalla and colleagues[121]. By
comparing Aβ uptake between primary hippocampal neu-
ronsandendothelialcells,theauthorsreportedthatwhilethe
latter requires endocytosis to internalize soluble Aβ,n e u r o n s
c a nt a k eu ps o l u b l eA β by passive diﬀusion [121]. Neuronal
u p t a k eo fs o l u b l eA β was unaﬀected by low temperature or
low glucose, suggesting that neuronal internalization of AβInternational Journal of Alzheimer’s Disease 7
is not mediated by energy-dependent processes including
endocytosis [121]. There are biophysical data supporting
this conclusion, such that both Aβ40 and Aβ42 intercalate
into phospholipid bilayers [122]. It is not unreasonable to
propose that endocytosis and passive diﬀusion of Aβ can
coexist in the same neuron. Further investigation is needed
to reconcile the seemingly contradicting results in regards to
studies showing endocytosis-dependent Aβ uptake.
6. FutureDirections and Conclusions
With the recent wealth of novel ﬁndings, our understanding
of neuronal Aβ uptake has improved since the original dis-
covery of intraneuronal Aβ in AD brains. Cumulatively, the
current data implicate several distinct pathways of entry for
extracellular Aβ (Table 1). Lipid raft-dependent endocytosis
is the predominant Aβ uptake mechanism although lipid
raft-independent endocytosis and nonendocytic pathways
also exist. Lipid components such as cholesterol and sphin-
golipids have a role in modulating Aβ endocytosis as well
as recruiting Aβ to the lipid raft. Questions remain as to
w h e t h e rl i p i d sc a na c ta sc a r r i e r so fA β uptake independent
of lipoprotein chaperones and receptor proteins. It may be
the case that lipid components and raft-associated receptors
synergistically carry Aβ into the cell. Further investigations
are needed to address these speculations. There is also little
data on the long-term eﬀects of internalized Aβ,w h i c hi s
found not only in endocytic pathways but also in other
compartments including the cytosol. In vitro studies in
general found that internalized Aβ cause lysosomal leakage
and neurotoxicity,butwhether the same occurs in vivo in the
presence of physiological buﬀers is yet to be determined. In
fact, most of the mechanisms of Aβ uptake have not been
investigated in animal models. The wealth of culture studies
has nonetheless demonstrated the potential importance of
Aβ uptake mechanisms in the pathogenesis of AD.
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